Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Immunovia

0.16 SEK

-1.61 %

Less than 1K followers

IMMNOV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Immunovia

2019202020212022202320242025
Revenue0.40.40.81.21.60.90.7
growth-%1.7 %133.1 %36.3 %37.4 %-41.1 %-26.3 %
EBITDA-105.8-84.6-147.6-166.2-154.7-96.0-78.1
EBIT-114.2-134.3-166.6-191.2-296.5-109.4-80.4
Profit before taxes-114.5-146.0-156.0-168.1-309.4-76.5-145.9
Net income-114.5-146.0-156.0-168.1-309.4-76.5-145.9
EPS-2.10-2.45-2.47-2.66-3.07-0.72-0.42
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%-29,719.7 %-23,359.1 %-17,484.0 %-14,455.7 %-9,793.7 %-10,321.5 %-11,395.6 %
EBIT-%-32,092.1 %-37,111.3 %-19,742.7 %-16,621.7 %-18,763.3 %-11,764.5 %-11,735.0 %
ROE-32.0 %-24.4 %-35.9 %-68.9 %-461.9 %-657.0 %-225.4 %
ROI-27.3 %-22.1 %-31.6 %-55.9 %-313.6 %-231.7 %-165.4 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.